Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

2024-514746-36-00 Protocol OMTX705-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 20 Oct 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 11 sites · Protocol OMTX705-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 128
Countries 1
Sites 11

Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

Key facts

Sponsor
Oncomatryx Biopharma S.L.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
20 Oct 2022 → ongoing
Decision date (initial)
2024-07-01
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-514746-36-00
EudraCT number
2021-002666-40

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oncomatryx Biopharma S.L.

Sponsor organisation
Oncomatryx Biopharma S.L.
Address
Parque Tecnologico De Bizkaia 801b 2p
City
Derio
Postcode
48160
Country
Spain

Scientific contact point

Organisation
Oncomatryx Biopharma S.L.
Contact name
Chief Medical Officer

Public contact point

Organisation
Oncomatryx Biopharma S.L.
Contact name
Chief Medical Officer

Locations

1 EU/EEA country · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 113 11
Rest of world
United States
15

Investigational sites

Spain

11 sites · Ongoing, recruiting
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Fundacion Onkologikoa Fundazioa
Onkologikoa, Pasealeku Doct. Begiristain 121, 20014, Donostia
Institut Catala D'oncologia
Medical Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Clinica Universidad De Navarra
Oncology, Avenue Pio XII 36, 31008, Pamplona
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario Donostia
Medical Oncology, Pasealeku Doct. Begiristain 109, 20014, Donostia
MD Anderson Cancer Center
Oncology, Calle De Arturo Soria Nº 270, 28033, Madrid
Complexo Hospitalario Universitario De Santiago
Oncology, Calle Choupana Da S/n, 15706, Santiago De Compostela
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-10-20 2022-10-20

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-19 Spain Acceptable
2024-07-01
2024-07-01
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-30 Spain Acceptable
2024-11-28
2024-12-04
3 SUBSTANTIAL MODIFICATION SM-2 2025-07-09 Spain Acceptable
2025-09-03
2025-09-05
4 SUBSTANTIAL MODIFICATION SM-3 2026-01-13 Spain Acceptable
2026-03-31
2026-04-22